Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

Prior treatment

• Any history of ongoing, significant infections or recent serious infection, i.e., requiring hospitalization and or IV antimicrobial treatment in the 3 months prior to screening
• Severe chronic obstructive pulmonary disease or known lung disease except for mild asthma treated with bronchodilators
• Surgery or trauma (e.g. contusions, abrasions, stab wounds, cutting wounds, crush injuries, impact injuries, and firearm injuries etc.) within 14 days before enrollment that are not approporiate to participate in study in investigators' opinion
• Corticosteroid usage at a high dose (i.e., IV or IM corticosteroids or use of oral prednisone equivalent \>10 mg/day) or not at a stable dose for the treatment of RA or other diseases within 28 days prior to randomization.
• Already participating in another interventional clinical trial or participated in another interventional clinical trial within 3 months before screening

Other illness

• Infections of hepatitis B, hepatitis C, active or latent tuberculosis, or positive for human immunodeficiency virus (HIV)1 or HIV2
• Any active inflammatory diseases other than RA
• Any coexistent active major medical diagnosis of clinically significant cardiovascular, neurological psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion
• History of cerebrovascular accident (stroke) within 1 year before screening
• Clinically significant heart disease (New York Heart Association, class III and class IV)
• Clinical history of malignancy with the exception of adequately treated cervical carcinoma in situ or basal cell carcinomas

Lab values

• Serum aminotransferase (ALT or AST) levels ≥ 2x upper limits of normal
• Creatinine clearance rate (Ccr) \< 45 ml/min calculated by Cockcroft-Gault formula
• Known allergies or had a history of allergy to minor molecular heparinum and human serum albumin that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion

Other

• Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study and for twelve months after completing the study infusion, unless surgically sterilized or postmenopausal during the study
• Other situations that are not approporiate to participate in study in investigators' opinion

• Male or female patients aged 18 to 65 (inclusive)
• Patients who are diagnosed with rheumatoid arthritis following the 2010 ACR/EULAR classification criteria
• Patients who still remain moderate-to-high disease activity, i.e. DAS28\>3.2 at screening and study baseline, after standard csDMARDs therapy
• Patients who are positive for rheumatoid factors (RF) and/or anti-CCP antibody
• Patients who are clinically stable with no significant changes in physical condition from screening to study baseline
• Patients who are available and willing to comply with all study procedures
• Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines